Deciphering the Metabolism of Haematological Cancers
It has long been realised that metabolism is central to cellular development, proliferation and homeostasis. Collectively, aberrations in metabolism are now recognised as a major hallmark of cancer, opening new avenues for persona...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2014-60507-JIN
IDENTIFICACION DE DETERMINANTES MOLECULARES Y NUEVAS DIANAS...
206K€
Cerrado
cONCReTE
DevelOpmeNt of Cancer RNA TherapEutics
2M€
Cerrado
PID2021-126543OB-C22
PROCESADO DE SEÑAL EN METABOLOMICA CUANTITATIVA DIRIGIDA Y D...
182K€
Cerrado
PID2019-107557RB-I00
TARGETEANDO LA COAGULACION EN LA FORMACION DE METASTASIS EN...
145K€
Cerrado
EUIN2015-62801
DESCUBRIMIENTO DE OBJETIVOS METABOLICOS PARA EL DESARROLLO D...
16K€
Cerrado
SAF2015-66084-R
AVANZANDO EN LA INTERPRETACION DE GENOMAS DE TUMORES PARA ME...
290K€
Cerrado
Información proyecto HaemMetabolome
Duración del proyecto: 49 meses
Fecha Inicio: 2015-08-07
Fecha Fin: 2019-09-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
It has long been realised that metabolism is central to cellular development, proliferation and homeostasis. Collectively, aberrations in metabolism are now recognised as a major hallmark of cancer, opening new avenues for personalised medicine. As haematological malignancies are multi-factorial diseases, our main emphasis will be on the integration of biomedical multi-omics data and computational systems modelling with the ultimate aim to understand metabolic regulation in haematological cancers. HaemMetabolism is design to unravel the regulatory mechanisms that link cell cycle control and metabolism. For this we will screen a panel of haematological cancer cell lines for the metabolic phenotypes and against a library of inhibitors. Gene-function analyses will be performed using shRNA libraries directed against key metabolome regulators. Validation will occur in primary patient samples in vitro and in vivo in preclinical humanized niche xenograft mouse models. A systems biomedicine approach will be integrated build genome-scale transcriptional models that explain deregulated metabolic pathways relevant for the development of haematological malignancies. This work will not only open new avenues for drug discovery but will also provide a multi-disciplinary framework for student training in biomedical technologies.